News
COBEST was the first prospective head-to-head comparison of Atrium's Vascular V12 balloon expandable covered stent versus bare metal stents (BMS) for the treatment of a specific type of Peripheral Arterial Disease (PAD) known as aorto-iliac occlusive disease. The study's principal investigator, Professor Patrice Mwipatayi, M.D., is head of vascular surgery at Royal Perth Hospital in Perth, Australia.
Dr. Mwipatayi has provided this statement regarding COBEST: "This was the first prospective, randomized, multi centre, controlled trial comparing balloon expandable covered stents directly to bare metal stents. One striking result from the COBEST study was the 5 times lower TVR rate with Atrium's V12 compared to BMS. This poses a tremendous global economic benefit along with a tremendous quality of life benefit for our patients who are being treated for peripheral vascular disease and more specifically aorto-iliac disease."
LINC 2018: BIOFLEX PEACE and BIOLUX 4EVER support concept of low metal burden therapies in the superficial femoral artery
Dr. Patrice Mwipatayi, Professor of Vascular Surgery, Royal Perth Hospital, Perth, Australia, introduced the REACT (REsponse Adapted Combination Therapy) pilot study to evaluate different imaging modalities in assessing the need for stenting following DCB treatment in SFA lesions. This will be a new genre of study designed to collect scientific data in order to support physician decision-making based on vessel response.
